| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
BioArctic AB (publ) (ST: BIOA-B)
BIOA-B Technical Analysis
5
| As on 9th Jun 2023 BIOA-B STOCK Price closed @ 356.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 125.66 & Strong Buy for SHORT-TERM with Stoploss of 105.89 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BIOA-BSTOCK Price
| Open | 337.40 | Change | Price | % |
| High | 356.80 | 1 Day | 19.60 | 5.83 |
| Low | 332.40 | 1 Week | 49.00 | 15.96 |
| Close | 356.00 | 1 Month | 119.80 | 50.72 |
| Volume | 487614 | 1 Year | 238.00 | 201.69 |
| 52 Week High 338.20 | 52 Week Low 67.05 | ||||
ST Sweden Most Active Stocks
| QUIA | 0.02 | 0.00% |
| QLIFE | 0.04 | 0.00% |
| SBB-B | 5.38 | 3.07% |
| STRLNG | 0.12 | 33.33% |
| LUNE | 21.97 | 6.65% |
| SAS | 0.36 | 5.88% |
| URBIT | 0.02 | 0.00% |
| IDOGEN | 0.15 | -31.82% |
| STAR-B | 0.89 | -1.11% |
| TELIA | 24.60 | 0.41% |
ST Sweden Top Gainers Stocks
ST Sweden Top Losers Stocks
| BIOA-B Daily Charts |
BIOA-B Intraday Charts |
Whats New @ Bazaartrend |
BIOA-B Free Analysis |
|
|
BIOA-B Important Levels Intraday
| RESISTANCE | 403.02 |
| RESISTANCE | 387.94 |
| RESISTANCE | 378.62 |
| RESISTANCE | 369.30 |
| SUPPORT | 342.70 |
| SUPPORT | 333.38 |
| SUPPORT | 324.06 |
| SUPPORT | 308.98 |
BIOA-B Forecast May 2024
| 4th UP Forecast | 407.64 |
| 3rd UP Forecast | 391.08 |
| 2nd UP Forecast | 380.84 |
| 1st UP Forecast | 370.61 |
| 1st DOWN Forecast | 341.39 |
| 2nd DOWN Forecast | 331.16 |
| 3rd DOWN Forecast | 320.92 |
| 4th DOWN Forecast | 304.36 |
BIOA-B Weekly Forecast
| 4th UP Forecast | 384.52 |
| 3rd UP Forecast | 375.37 |
| 2nd UP Forecast | 369.72 |
| 1st UP Forecast | 364.07 |
| 1st DOWN Forecast | 347.93 |
| 2nd DOWN Forecast | 342.28 |
| 3rd DOWN Forecast | 336.63 |
| 4th DOWN Forecast | 327.48 |
BIOA-B Forecast2024
| 4th UP Forecast | 915.02 |
| 3rd UP Forecast | 735.74 |
| 2nd UP Forecast | 624.92 |
| 1st UP Forecast | 514.1 |
| 1st DOWN Forecast | 197.9 |
| 2nd DOWN Forecast | 87.08 |
| 3rd DOWN Forecast | -23.74 |
| 4th DOWN Forecast | -203.02 |
BioArctic AB (publ) ( ST Sweden Symbol : BIOA-B )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BIOA-B Business Profile
BioArctic AB (publ), a research intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disease in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 3 clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia/traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer's disease. The company also develops BAN0805, an anti-alpha-synuclein antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer's disease; imaging and biochemical biomarkers for Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. The company has collaborations with Eisai and AbbVie; a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostics for Alzheimer's disease; and a research collaboration agreement with University of Oslo. It also has a joint research agreement with Alligator Bioscience AB (publ) to employ its proprietary antibody generation technologies for developing new product candidates. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden. Address: Warfvinges vag 35, Stockholm, Sweden, 112 51
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service